ALSO NOTED: Aventis settles fraud claims; Novartis CEO critiques U.S. healthcare;

> Aventis Pharmaceuticals will pay $190 million to settle claims of drug-pricing fraud. The payment will be divided among the federal government and several states. Report

> Bayer is taking over the California plant that produces its Betaseron multiple sclerosis drug. The facility had been operated by Chiron. Report

> A private equity firm focused on healthcare has wooed away a Johnson & Johnson group chairman. In joining Water Street Healthcare Partners as operating partner, Curt Selquist will become another in a veritable cornicopia of ex-healthcare execs at the firm.  Release

> Mylan Pharmaceuticals got tentative FDA approval for its formulation of Topiramate, a generic version of Ortho McNeil's Topamax drug. Release

And Finally... In a New York Times Q&A, Novartis CEO Daniel Vasella critiqued the U.S. healthcare system and assessed his own industry. One highlight: He blamed the high cost of new drugs in part on an overcautious FDA. Article 

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.